Nuwellis, Inc. Announces Definitive Agreements for Warrant Exercises

MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) —

Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.

Nuwellis, Inc. has made significant strides in the medical device industry with their commitment to transforming the lives of people with fluid overload. The recent announcement of definitive agreements for warrant exercises demonstrates the company’s strong financial position and investor confidence. With total gross proceeds of approximately $3.8 million from the exercise of outstanding warrants, Nuwellis, Inc. is poised for further growth and development.

The additional $1.3 million of gross proceeds received through warrant exercises over the last week further solidifies Nuwellis, Inc.’s financial stability and ability to fund ongoing research and innovation. This influx of capital will undoubtedly support the company’s mission to provide life-changing medical devices to those in need.

How This Will Affect Me

As a potential investor, the announcement of Nuwellis, Inc.’s definitive agreements for warrant exercises may present new opportunities for financial growth and portfolio diversification. The company’s strong performance and commitment to transforming healthcare services could result in favorable returns for shareholders.

How This Will Affect the World

Nuwellis, Inc.’s continued success in the medical device industry has the potential to positively impact the world by improving patient outcomes and quality of life for individuals with fluid overload. The company’s innovative solutions and commitment to healthcare transformation could set a new standard for medical device companies globally.

Conclusion

The announcement of Nuwellis, Inc.’s definitive agreements for warrant exercises marks a significant milestone for the company and the medical device industry as a whole. With a strong financial position and investor confidence, Nuwellis, Inc. is well-positioned for continued growth and success in transforming the lives of people with fluid overload.